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Rho-associated coiled-coil protein kinase 1 (ROCK-1) is a direct
cleavage substrate of activated caspase-3, which is associatedwith
heart failure. In the course of human heart failure, we found
marked cleavage of ROCK-1 resulting in a 130-kDa subspecies,
which was absent in normal hearts and in an equivalent cohort of
patientswith left ventricular assist devices.Murine cardiomyocytes
treated with doxorubicin led to enhanced ROCK-1 cleavage and
apoptosis, all of which was blocked by a caspase-3 inhibitor. In
addition, a bitransgenic mouse model of severe cardiomyopathy,
which overexpresses Gq protein and hematopoietic progenitor
kinase-germinal center kinase-like kinase, revealed the robust
accumulation of the 130-kDa ROCK-1 cleaved fragment. This con-
stitutively active ROCK-1 subspecies, when expressed in cardiomy-
ocytes, led to caspase-3 activation, indicating a positive feed-
forward regulatory loop. ROCK-1-dependent caspase-3 activation
was coupled with the activation of PTEN and the subsequent
inhibition of protein kinase B (Akt) activity, all of which was
attenuated by siRNAdirected against ROCK-1 expression. Similarly,
ROCK-1-null mice (Rock-1/) showed a marked reduction in myo-
cyte apoptosis associated with pressure overload. These data
suggest an obligatory role for ROCK-1 cleavage in promoting
apoptotic signals in myocardial hypertrophy andor failure.
heart failure  left ventricle assist device  phosphatase and tensin homolog
deleted on chromosome ten
Heart failure is an eventual outcome for diverse cardiovasculardisorders and the leading cause of combined morbidity and
mortality in the United States and other developed industrial
nations (1). Diverse signal transduction pathways, G proteins and
protein kinases among them, likely contribute to heart failure, and
the identification of essential control points have both fundamental
and translational importance (2, 3). Recent findings suggest a role
for the activation of the apoptotic cascade in heart failure, which
may involve the activation of proteolytic caspase-3 and cardiomy-
ocyte loss (1, 4). Although the level of apoptosis detected in the
failing heart are variable (4–6), a low prevalence of apoptosis is
sufficient to cause cardiac contractile depression (7). Accounting
for the most conservative rate of cardiomyocyte death, the normal
heart would lose most of its mass in a few decades, but the senile
and failing heart lose myocytes in a matter of several months to a
few years (8). This dilemma raised the issue of the imbalance
between the continual loss of cardiomyocytes and the long interval
for the chronic progression in heart failure. There are critical
deficiencies in the available information regarding the relationship
between apoptosis in the failing heart and depressed contractile
function. Other mechanisms might contribute to heart failure
besides cell loss. For example, we showed that activated caspase-3
mediated the cleavage of serum response factor (SRF). Cleaved
SRF became a dominant negative factor that down-regulated SRF
target genes, many of which are contractile proteins (9). Therefore,
the identification of other caspase-specific substrates may yield new
insights into apoptosis-related cardiac depression.
Cellular membrane blebbing, a hallmark of cellular apoptosis,
has led to the identification of Rho-associated coiled-coil protein
kinase 1 (ROCK-1), one of only two isoforms that gets constitu-
tively activated by caspase-3 cleavage in fibroblasts (10–12). ROCK
is a downstreammediator of RhoA and is believed to play a critical
role in mediating the effects of RhoA on stress fiber formation,
smooth muscle contraction, cell adhesion, membrane ruffling, and
cell motility (13, 14). The RhoROCK pathway is an attractive
candidate in the pathogenesis of heart failure, with a potential role
in both ventricular remodeling and impaired peripheral vascular
resistance (15, 16). We asked whether endogenous ROCK-1 was
cleaved in heart disease, and if so, what the functional consequences
were. Myocardial ROCK-1 was found to be a natural substrate for
caspase-3 cleavage in human heart failure and in genetic cardio-
myopathy mouse models. Here, we observed truncated ROCK-1-
facilitated caspase-3 activation, which led to a feed-forward loop
promoting apoptosis. Loss-of-function studies in cultured cardio-
myocytes with ROCK-1 siRNA significantly decreased cardiac
apoptosis induced by ceramide. In ROCK-1-null mouse mutants
(ROCK-1/), we observed reduced apoptosis in response to
pressure overload. Furthermore, cleaved ROCK-1 also led to the
activation of PTEN (phosphatase and tensin homolog deleted on
chromosome ten) and subsequent inhibition of the protein kinase
B (Akt) survival pathway. Caspase-3-mediatedROCK-1 cleavage is
a functionally important activator of the apoptotic pathway asso-
ciated with cardiac overload andor failure.
Results
Demographics. Table 1 shows the demographics of the human
population studied, in which all 23 patients were in the New York
Heart Association functional class III or IV with a left ventricle
ejection fraction of 20%. Ten patients underwent placement of
left ventricle assist device (LVAD) support for progressive cardiac
deterioration (despite maximal i.v. inotropic support) and impend-
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ing end-organ failure. The mean duration of LVAD support was
41  10 days (range 14–91 days).
ROCK-1 Cleaved in Human Failing Hearts and Rescued by Ventricular
Mechanical Support. Because caspase-3 was activated in human
heart failure (9, 17), and the consensus recognition sequence
DETD (at amino acid position 1113) for caspase-3 cleavage was a
conserved sequence in ROCK-1 mammalian species (Fig. 1A), we
asked whether ROCK-1 cleavage occurred in failing human hearts.
Ventricular myocardial samples were collected from 13 patients
with end-stage heart failure at the time of transplant, 7 patients who
died of noncardiac causes (control group), and 10 patients with
end-stage heart failure who were being maintained on LVAD
support awaiting transplantation (Fig. 1B). Protein blot analysis
detected a ROCK-1 fragment of 130 kDa in all failing hearts
without LVAD support, corresponding to the predicted ROCK-1
cleavage product, in addition to the 160-kDa native protein. In
contrast, normal hearts and failing hearts with LVAD support
contained only the intact 160-kDa protein. As Chang et al. (9) and
Narula et al. (17) reported, a significant increase in caspase-3
activity was observed in nontreated failing hearts when compared
with either the normal hearts or the failing hearts treated with
LVAD. The cleavage of poly(ADP-ribose) polymerase (PARP), a
known caspase-3 substrate, was also observed (Fig. 1B). Thus,
increased caspase-3 activity in failing hearts was accompanied by
the cleavage of ROCK-1 and the reciprocal appearance of a
ROCK-1 subspecies that corresponded to the predicated cleavage
product. To further confirm that the 130-kDa fragment was cleaved
ROCK-1, we used a second antibody specific against theC-terminal
end of ROCK-1 (epitope maps between residues 1300–1354). Only
the 160-kDa full-length ROCK-1 was detected in the hearts of all
patient groups (Fig. 1C). Densitometry analyses of ROCK-1 cleav-
age pooled from several Western blots for all of the 13 heart failure
patients, 10 LVAD patients, and 7 normal controls were summa-
rized in Fig. 1D. Statistical analysis showed a significant (P 0.001)
difference between failing heart and normal heart samples for the
presence of the cleaved subspecies. Reduced amounts of ROCK-1
cleavage were apparent in patients placed on LVAD (P  0.001),
whereas ROCK-1 cleavage in the LVAD group did not appear
differently from the control cohorts (Fig. 1D). No significant
differences were observed among all groups of patients for levels of
the native full-length ROCK-1 protein. Moreover, we did not
observe any differences in ROCK-1 cleavage with regard to the
etiology of heart failure.
ROCK-1 Was Cleaved by Caspase-3 in Apoptotic Cardiomyocytes and
Genetic Models ofMurine Heart Failure.Neonatal rat cardiomyocytes
were subjected to doxorubicin treatment, a potent apoptotic trigger,
at 10 M for 20 h. The cleaved 130-kDa ROCK-1 subspecies
appeared in doxorubicin-treated myocytes, which also paralleled
Table 1. Demographics of human heart failure patients
Patient
without
LVAD Agesex Diagnosis
Patient
with
LVAD Agesex Diagnosis
Implant
duration,
days
1 63/M ICM 1 49/M ICM 21
2 60/M ICM 2 66/M DCM 90
3 69/M ICM 3 61/M DCM 35
4 54/M ICM 4 48/F DCM 15
5 56/F DCM 5 60/F CDM 14
6 54/M DCM 6 57/M DCM 21
7 69/M DCM 7 44/F DCM 91
8 41/M DCM 8 70/M ICM 14
9 53/F DCM 9 44/M DCM 61
10 67/M ICM 10 42/M DCM 43
11 54/M ICM
12 64/M ICM
13 52/F HCM
ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; HCM,
hypertrophic cardiomyopathy; M, male; F, female.
Fig. 1. ROCK-1 cleaved in human failing hearts. (A) A schematic diagram of
ROCK-1 structural domains. The caspase-3 consensus cleavage sequence
(DETD, amino acids 1110–1113) is conserved among ROCK-1 genes in mam-
mals. Cleavage of ROCK-1 removes the inhibitory C terminus, generating a
130-kDa fragment with constitutive kinase activity. (B) Representative West-
ern blots of human myocardial samples. ROCK-1 protein levels were assessed
from myocardial samples taken from patients with end-stage heart failure
with andor without LVAD treatment and from normal hearts. An increase in
caspase-3 activity was observed in human failing hearts, which returned to
control levels after LVAD treatment. Cleavage of PARP, a known caspase-3
substrate during apoptosis, is also shown as an internal control. Even protein
loading for PAGE was shown by a blot probed with a specific antibody against
-actin. (C) A specific antibody directed against the C-terminal end of ROCK-1
detected only full-length ROCK-1 in all patient groups. NS, nonspecific. (D)
Densitometric analysis of cleaved ROCK-1 and full-length ROCK-1 levels were
taken from two to three replicates that covered 13 heart failure patients, 10
LVAD patients, and 10 noncardiac disease control patients. The statistical
analysis showed a significant difference (P  0.001) in comparison between
failing myocardium samples and normal myocardium samples in the cleaved
ROCK-1 subspecies (130 kDa).
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the cleavage of PARP (Fig. 2A). Cleavage of ROCK-1 and PARP
was blocked by a caspase-3 inhibitor, Z-VAD-fmk. Next, caspase-3
activity was induced by introducing dimerizer-dependent caspase-3
via adenovirus, Ad-GiCasp 3 (Fig. 2B) (18). The adenovirus
expresses a caspase-3 precursor fusion gene linked in-frame with a
modified FK506-binding domain and chemical inducer binding
domain, the binding site for a chemical inducer of dimerization
(CID). Adding CID brings together the modified caspase-3 pre-
cursors, leading to its activation and rapid cellular apoptosis.
ROCK-1 remained intact after Ad-GiCasp 3 infection of cardio-
myocytes, but after the addition of CID, ROCK-1 cleavage pro-
ceeded with the appearance of the 130-kDa subspecies, along with
PARPcleavage. Thus, activated caspase-3 induced by forced dimer-
ization caused ROCK-1 cleavage (Fig. 2C).
To determine whether ROCK-1 cleavage occurred in the intact
heart, we took advantage of transgenic mouse lines that display
cardiomyopathies. One line expresses Gq, a pivotal G protein for
diverse hypertrophic signals in the heart with a predisposition to
apoptosis (19). Hematopoietic progenitor kinase-germinal center
kinase-like kinase (HGK, MAP4K4), an upstream mediator of
cytokine signaling, imposes little or no baseline phenotype in the
heart but induces florid apoptotic cardiomyopathy in concert with
Gq (M.X. and M.D.S., unpublished results). Hearts from MHC-
Gq, MHC-HGK, and bigenic MHC-Gq-HGK transgenic mice
were analyzed by using protein immunoblots. As indicated in Fig.
2 D and E, the clipped 130-kDa ROCK-1 fragment was observed
in hearts from bigenic mice, which coincided with a significant
increase in caspase-3 activity. CleavedROCK-1 fragments were not
detected in mice inheriting overexpression of only HGK or Gq
transgenes, although a small increase in caspase-3 activity was
measurable in Gq hearts that was probably insufficient to induce
ROCK-1 cleavage. Specificity of the clipped subspecies was con-
firmed by a second antibody that is specific only for the C-terminal
end of ROCK-1 and that revealed only the 160-kDa full-length
species of ROCK-1 and not the 130-kDa cleaved species (Fig. 2F).
Because increased cleaved ROCK-1 correlated well with a high
level of caspase-3 activity observed in bigenic Gq-HGK mice, we
then asked whether ROCK1, a ROCK-1 cleavage mutant, would
activate caspase-3.
ROCK1 Supported Caspase-3 Activation. Cardiomyocytes were
transfected with a ROCK1 expression vector, a C-terminally
truncated mutant (amino acids 1–1080), which closely corre-
sponded to the caspase-3 cleaved activated species (amino acids
1–1113) (10, 11). A second plasmid, pCaspase-3-sensor, encoding
an EYFP fusion protein (Fig. 3A), was cotransfected, which pro-
vided a visual readout of cleaved ROCK-1 after caspase-3 activa-
tion. Caspase-3-dependent cleavage was quantified by counting the
number of transfected myocytes in which the fluorescent fusion
proteins were translocated to nuclei. Expressed ROCK1 caused a
3-fold increase of caspase-3 activity and inflicted myofilament
damage, which were not observed with full-length ROCK-1 or the
control expression vector (Fig. 3 B and C). Thus, the truncated,
constitutively active ROCK-1 was sufficient to induce caspase-3
activation, indicative of a feed-forward regulatory loop, whereby
ROCK-1 cleavage caused further caspase-3-dependent cleavage
and further activation of ROCK-1.
ROCK-1 Knockout Prevented Apoptosis Induced by Ceramide in Cul-
tured Cardiomyocytes or in Mice Subjected to Systolic Overload.
Would blocked expression of endogenous ROCK-1 protect cardi-
omyocytes against apoptosis induced by apoptotic stimuli? We
applied a specific siRNA to significantly knock down ROCK-1
expression in cardiomyocytes without blocking expression of the
other Rho kinase isoform, ROCK-2 (Fig. 4A Top Left). ROCK-1
siRNA inhibited caspase-3 activation induced by ceramide (Fig. 4A
Upper Right). Fluorescent staining showed that pretreatment with
siRNA-protected cardiomyocytes against ceramide-induced apo-
ptosis andprotectedmyofilament organization in comparison to the
disorganized and damaged myofilaments in non-siRNA-treated
cells (Fig. 4B). Without siRNA treatment, ceramide strongly in-
duced caspase-3 activation along with apoptosis.
To substantiate the role of ROCK-1 in this proteolytic cascade
process in vivo, ROCK-1-null mice, which are viable (15), were
subjected to severe pressure overload as a pathophysiological
signal for apoptosis (15, 20). Consistent with the siRNA results,
we found that ROCK-1/ mice exhibited significantly reduced
TUNEL-positive cardiac myocytes (46 myocytes per 105 nuclei)
compared with WT mice (93 myocytes per 105 nuclei, P  0.05)
when subjected to pressure overload through aortic banding for
Fig. 2. ROCK-1 cleaved by caspase-3 in apoptotic cardiomyocytes and in
transgenic heart failure mouse models. (A) A Western blot of whole-cell
lysates from controls and doxorubicin-treated (Dox) neonatal rat cardiomyo-
cytes revealed enhanced ROCK-1 and PARP cleavage. Caspase-3 inhibitor
Z-VAD-fmk blocked caspase-3 cleavage. (B) A schematic diagram of a dimer-
izer inducible activation system for caspase-3. An adenovirus expressed a
caspase-3 precursor fused to a modified FK506-binding domain, and a chem-
ical inducer binding domain. Dimerization of caspase-3 precursors via CID
forces caspase-3 activation and rapid cellular apoptosis. (C) A Western blot of
whole-cell lysates from neonatal rat cardiomyocytes showed intact ROCK-1
after caspase-3 adenovirus infection. The addition of CID led to ROCK-1
cleavage shown by the appearance of the 130-kDa species. Control adenovirus
express -gal. (D and E). To assess ROCK-1 cleavage in vivo, hearts from Gq,
HGK, and bigenic Gq-HGK mice were assessed by Western blot analysis for
ROCK-1 and caspase-3 activity. A 130-kDa fragment of ROCK-1 was observed
only in hearts from bitransgenic mice paralleled with a significant increase in
caspase-3 activity. (F) The same heart specimens assessed by a specific antibody
against C-terminal ROCK-1 revealed only a full-length species of ROCK-1.
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1 week (Fig. 4 C and D). Therefore, both in vitro and in vivo data
suggest that ROCK-1 played an essential role in cardiac apo-
ptosis, and disrupted ROCK-1 expression contributed to myo-
cardial protection.
Caspase-3 Activation by ROCK1 Induced PTEN Activation and Akt
Inhibition. The PI3KAkt is a central component of several recep-
tor-mediated survival pathways (21). PTEN is a PI3K upstream
negative regulator (22, 23) and is phosphorylated by ROCK-1 in
vitro (24). In addition, bioactive lipid sphingosine 1-phosphate
activates PTEN via a Rho GTPase-dependent pathway (25). To
elucidate a mechanism involved in ROCK-1-dependent caspase
activation, we tested for potential changes in the PI3KAkt cell
survival pathway (21) and for PTEN activity after transfection of
ROCK1 expression vectors into human HEK cells. ROCK1
decreased the phospho-Akt (pAkt) level by 30% (Fig. 5A) and
increased PTEN activity by 2-fold in comparison with the control
(P  0.05). No change in activity was found with either full-length
ROCK-1 or a kinase-deficient mutant, ROCK-1KD expression
vectors (Fig. 5B). Therefore, the repression of Akt activity by
ROCK1 may contribute to its proapoptotic effect through in-
creased PTEN activity. This hypothesis was substantiated by a 65%
increase in the basal phosphorylation level of Akt after blocked
PTEN expression by siRNA treatment (Fig. 5C). In addition,
decreased pAkt activity caused by ROCK1 was reversed by
blocked PTEN expression (Fig. 5D). Furthermore, the levels of
pAkt showed a 55% increase in ROCK-1-null mouse hearts when
subjected to 1 week of aortic banding compared with the banded
WT hearts (Fig. 5E). Therefore, the increase in PTEN activity and
the subsequent decrease in Akt activity (dephosphorylation) may
contribute to the proapoptotic effect of ROCK1.
Fig. 3. Activated mutant, ROCK1, induced caspase-3 activation and apo-
ptosis in neonatal rat cardiomyocytes. (A) Schematic diagram of a caspase-3
sensor, which incorporated a caspase-3-specific cleavage site located between
EYFP and NES. When caspase-3 is inactive, the dominant NES targets EYFP to
the cytosol. After the induction of apoptosis, the export signal is removed by
active caspase-3, which triggers the redistribution of EYFP from cytosol to the
nucleus via NLS (nuclear localization signal). (B) Representative images
showed cardiac myocytes subjected to ROCK1 accumulated EYFP in myocyte
nuclei indicated by arrows and developed apoptosis, as shown by disorga-
nized myofilaments. Green, EYFP-fusion protein; red, rhodamine-conjugated
phalloidin staining for F-actin; blue, DAPI nucleus staining. (C) The prevalence
of caspase-3 activation was evaluated by the percentage of transfected car-
diomyocytes exhibiting caspase-3 activation (nuclear localization of EYFP-
fusion protein). Results are the average  standard error of four separate
experiments.
Fig. 4. Blocked ROCK-1 expression reduced cardiomyocyte apoptosis. (A) A
specific siRNA knocked down ROCK-1 expression (Top Left). ROCK-1 siRNA
inhibited caspase-3 activation induced by ceramide (Upper Right). (B) Fluo-
rescent staining showed that pretreatment with the siRNA protected cardio-
myocytes from ceramide-induced apoptosis. (C) A representative ROCK-1/
mouse myocardium image showed a TUNEL-positive cardiac myocyte revealed
by TUNEL green staining after 1 week of aortic banding. (D) Comparison of
TUNEL-positive cardiac myocytes (per 105 nuclei) in left ventricle myocardium
from WT and ROCK-1/mice after 1 week of aortic banding or surgical sham.
n  5 mice for each group. NS, nonspecific; casp3, caspase-3. Red, phalloidin
staining for F-actin; blue, DAPI nucleus staining.
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Discussion
ROCK-1 is one of two isoforms, ROCK-1 and ROCK-2, of a
serinethreonine kinase identified as effectors of Rho GTPase
proteins, which mainly include RhoA, Rac1, and Cdc42. They
regulate a wide variety of cellular processes including apoptosis (26,
27). The potential proapoptotic effect of Rho kinase has been
suggested by others (28), and pharmacologic inhibition of Rho
kinase significantly reduced the level of myocyte apoptosis induced
by ischemiareperfusion in an isolated perfused rat heart prepa-
ration (29). However, a limitation of these studies is the low
specificity of pharmacological Rho kinase inhibitors that fail to
distinguish ROCK-1 from ROCK-2 as well as other kinases (30–
32). By contrast, a genetic approach shown here readily revealed
specific roles for ROCK-1 versus ROCK-2. Highly selective block-
ades of ROCK-1 expression in cultured cardiomyocytes by appli-
cation of siRNA, as well as loss-of-function studies of the intact
mouse heart revealed cardiac protection against apoptosis.
ROCK-1 deficiency supported an essential role of ROCK-1 cleav-
age and activation in facilitating myocyte apoptosis associated with
cardiac overload andor failure.
Rho kinase’s proapoptotic role may be mediated via regulation
of actin cytoskeletal rearrangement, which in turn induced the
activation of the caspase cascade via the assembly of the death-
inducing signaling (28, 29, 33, 34). In addition, we demonstrated
that constitutively active ROCK-1 generated by cleavage was
sufficient to activate caspase-3 and lead to myocyte apoptosis, as
outlined in a schematic model (Fig. 5F). Thus, we provided
evidence that cleaved activated ROCK-1 directly activated the
caspase cascade machinery.
Consistent with our observation, other ROCK-1 mutant mice
were also viable, with no detectable cardiac phenotype under
physiological conditions (35, 36). Furthermore, null ROCK-1
mouse mutants did not impair the compensatory hypertrophic
response induced by pressure overload but developed less perivas-
cular and interstitial fibrosis (15), a finding supported by a recent
study in which the ROCK-1 haploid-insufficient mice showed less
perivascular fibrosis after hypertrophic stimuli (36).
The precise relationship among the multiple factors controlling
apoptosis in cardiac overload, hypertrophy, and failure may depend
on the fundamental initiating factors. It is obvious that increased
apoptosis precedes the onset of cardiac dysfunction in a discrete
systolic overload model. Other models beginning with genetic
induction of myocardial dysfunction are followed by systolic over-
load resulting from cardiac dilation. What is evident is that aug-
mented apoptosis contributes to the cleaved activatedROCK-1 that
plays a synergistic role in cardiac myocyte apoptosis. Cleaved
activated ROCK-1 in failing hearts may be one of the mechanisms
that facilitates myocyte apoptosis and initiates a further feed-
forward activation of caspase-3. Inhibition or deletion of ROCK-1
appears to abort this proteolytic cycle. The therapeutic potential of
these observations is attractive because the inhibition of ROCK-1
may be relatively safe.
Materials and Methods
Source of Human Myocardium. Failing myocardium came from 13
patients with end-stage heart failure at the time of transplant. An
additional group of 10 patients had been maintained on LVAD
until transplant. Samples obtained from 7 patients who died of
noncardiac causes were used as a control group. All of the myo-
cardiumwas obtained from the left ventricle apex. The Institutional
Review Board of Baylor College of Medicine approved the
protocol.
Cell Culture, Plasmid Constructs, and Recombinant Adenoviruses.
Neonatal rat cardiomyocytes were isolated and cultured in
DMEMF12 medium with 10% horse serum (DF10). For immu-
nostaining, cells were cultured on precoated (with 0.2% gelatin)
coverslips. Transfections were performed by using Lipofectamine
2000 (Invitrogen, Carlsbad, CA).Human embryonic kidney (HEK)
A293T cells were cultured in DMEM with 10% FBS. The cDNA
for full-length human ROCK-1 cloned into the pCAG-myc vector
(pCAG-ROCK-1) was kindly provided by Shuh Narumiya (Kyoto
University, Kyoto, Japan). The Asp718–MscI cDNA fragment
encoding ROCK1 mutant (residues 1–1080) was cloned into the
pCAG-myc vector (pCAG-ROCK1) (37). A single lysine at
residue 105 was replaced by alanine to generate a kinase-deficient
mutant, pCAG-ROCK-1KD. The adenoviral vector, Ad-GiCasp
3, expressing inducible caspase-3, was generously provided by
David Spencer and Kevin Slawin (Baylor College of Medicine).
Addition of CID, AP20187 (50 nM, 24 h; ARIAD, Cambridge,
Fig. 5. Regulation of PTEN and Akt by ROCK-1. (A) HEK cells were transfected
with ROCK1 and its kinase mutant KD (kinase-deficient mutant ROCK-1).
Cellular lysates were assessed for phospho-Akt (pAkt) by Western blot anal-
ysis. (B) PTEN activities were assessed by Malachite green assay after cells were
transfected with full-length ROCK-1 and its mutants. (C) PTEN and pAkt were
detected by Western blots after cells were treated by PTEN-specific siRNA.
Densitometry analysis for pAkt is shown at Right after normalization by actin
expression. (D) In cotransfection with PTEN-specific siRNA and ROCK1, PTEN
and pAkt levels were analyzed. The expression levels were normalized to actin
and are shown at Right. All experiments were conducted in human HEK cells.
1, active Rho kinase ROCK-1; a.u., artificial unit; NS-siRNA, nonspecific siRNA.
(E) Levels of pAkt were assessed by Western blot analysis in hearts from WT
and ROCK-1/ mice subject to either sham surgery or 1 week aortic banding
pressure overload. (F) A proposed model outlining the role of caspase-3
cleavage activation of ROCK-1 on cardiac dysfunction. ROCK-1 may be the
leading target for activated caspase-3 in failing myocardium. Cleavage-
activated ROCK-1 kinase generated a positive feed-forward loop for caspase
cascade activation. This proapoptotic effect is associated with the activation of
PTEN and the dephosphorylation of Akt.
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MA), provoked the aggregation and activation of caspase-3 along
with rapid apoptosis (18).
Apoptosis Assay and Immunofluorescence Analysis. Apoptosis was
evaluated in caspase-3 activity and poly(ADP-ribose) polymerase
(PARP) cleavage by Western blot analysis. With regards to apo-
ptotic cultured neonatal cardiomyocytes, a caspase-3 sensor (BD
Biosciences Clontech, Mountain View, CA) was introduced to
detect the onset of caspase-3 activity (Fig. 3A). The vector encodes
EYFP (enhanced yellow fluorescent protein) fused with NES
(nuclear export signal) and NLS (nuclear localization signal). A
caspase-3-specific cleavage site is located between EYFP and NES.
When caspase-3 is inactive, the dominant NES directs EYFP to the
cytosol. When apoptosis is induced, the export signal is removed by
active caspase-3, which triggers the redistribution ofEYFP from the
cytosol to the nucleus via NLS, and is quantified by counting the
number of transfected cells by the nuclear localization of fluores-
cent fusion protein over the total transfected cells. Alexa Fluor 594
phalloidin staining (Invitrogen Molecular Probes, Carlsbad, CA)
and DAPI staining were applied for F-actin and cellular nuclei
visualization, respectively.
Animal Models with Different Apoptotic Levels. Three transgenic
mouse lines with different apoptotic levels were used. HGK was
overexpressed inmousemyocardium by using theMHCpromoter
(38). Gerald Dorn (University of Cincinnati Medical Center, Cin-
cinnati, OH) kindly provided MHC-Gq mice (19). Bigenic mice
overexpressing Gq-HGK mice were generated by breeding HGK
with Gq mice. All experiments were performed in 10-week-old
mice with an isogenic FVBN background. No early lethality
resulted from cardiac overexpression of exogenous HGK and Gq
alone.
Application of siRNAs for ROCK-1 and PTEN Knockdown and Ceramide-
Induced Apoptosis. To knock downROCK-1 expression in neonatal
rat cardiomyocytes, 100 nM siRNA (Ambion,Austin, TX)was used
with cotransfection of caspase-3 sensor vector as described above.
The same amount of siRNA specific for PTEN (Ambion) was
applied to human HEK cells. Cells were treated with ceramide for
40 h after transfection at 50 gml for 2 h to induce apoptosis. For
each specific siRNA knockdown, three different siRNAs were
tested. Two of the effective siRNAs were chosen to conduct each
experiment.
ROCK-1 Knockout Mice.Generation and characterization of ROCK-
1/ mice have been described by Zhang et al. (15).
Transverse Aortic Banding.Transverse aortic bandingwas conducted
in 12-week-old adult WT and ROCK-1/ mice, N  6 mice for
each group (39). Briefly, both ROCK-1/ and WT mice received
a comparable load, based on the right-to-left carotid artery flow
velocity ratio (from 5:1 to 10:1) after constricting the transverse
aorta. As a control, a sham operation without occlusion was
performed on respective age-matched littermate mice.
Western Blot and Malachite Green Assay. The antibodies purchased
were anti-phospho-Aktser473 (Cell Signaling Technology, Danvers,
MA), anti-PTEN (Upstate, Lake Placid, NY), anti-ROCK-1 (N-
terminal, epitope maps between residues 755 and 840), caspase-3,
PARP, and -actin (Santa Cruz Biotechnology, Santa Cruz, CA).
To verify the cleaved ROCK-1, an anti-ROCK-1 C-terminal anti-
body (epitope maps between residues 1300 and 1354) was applied
(Bethyl Laboratories,Montgomery, TX). Protein samples forWest-
ern blot analysis were prepared and separated as described in ref.
40. Even loadings were confirmed by an antibody probed for
-actin. PTEN activity was evaluated by Malachite green assay,
used to measure the rate of phosphate release (Upstate). Five
hundred micrograms of cell lysate protein was used for immuno-
precipitation.
Statistical Analyses.Weanalyzed all data by using one-wayANOVA
(SigmaStat; SYSTAT, Richmond, CA). A P 0.05 was considered
significant. Data are presented as mean  SEM.
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